BioPorto A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THOXF research report →
About the company
BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical assessments and standard diagnostic procedures. Furthermore, it supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications, along with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays.
- CEO
- Carsten Buhl
- IPO
- 2019
- Employees
- 48
- HQ
- Hellerup, DK
Price Chart
- Market Cap
- $73.77M
- P/E
- -6.81
- P/S
- 13.89
- P/B
- 8.88
- EV/EBITDA
- -6.16
- Div Yield
- 0.00%
- Gross Margin
- 75.44%
- Op Margin
- -213.70%
- Net Margin
- -203.83%
- ROE
- -166.86%
- ROIC
- -114.38%
- Revenue
- $40.20M · 10.91%
- Net Income
- $-81,930,998 · -20.06%
- EPS
- $-0.15 · 11.76%
- Op Income
- $-85,898,988
- FCF YoY
- 8.39%
- 52W High
- $0.31
- 52W Low
- $0.15
- 50D MA
- $0.15
- 200D MA
- $0.21
- Beta
- 1.38
- Avg Volume
- 19.08K
Get TickerSpark's AI analysis on THOXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our THOXF coverage
Recent articles, reports, and earnings notes.
No research on THOXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THOXF report →Similar companies
Peers in the same neighborhood.